Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 2, 2009, Pages 255-261

  Kobashi, Haruhiko ^a   Takaguchi, Kouichi ^b   Ikeda, Hiroshi ^c   Yokosuka, Osamu ^d   Moriyama, Mitsuhiko ^e   Imazeki, Fumio ^d   Kage, Masayoshi ^f   Seriu, Taku ^g   Omata, Masao ^h   Sakaguchi, Kousaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g BRISTOL MYERS SQUIBB   (United States)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic hepatitis B; Entecavir; Japanese

Indexed keywords

ENTECAVIR; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENAL ULCER BLEEDING; ENTERITIS; ENTEROCOLITIS; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERVERTEBRAL DISK HERNIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPONDYLOLISTHESIS; TACHYCARDIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 58849157996     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05593.x     Document Type: Article

References (29)

1. Fact Sheet WHO/204 Hepatitis B. 2000. Geneva, Switzerland : World Health Organization, 2003 10 9.
2. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993 104 : 955 63.
3. Mohamed R, Desmond P, Suh DJ et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2004 19 : 958 69.
4. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000 15 : 1356 61.
5. Kao JH, Chen DS. The natural history of hepatitis B virus infection. In : Lai CL, Locarnini S, eds. Hepatitis B Virus. London : International Medical Press, 2002 161 72.
6. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993 119 : 312 23.
7. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999 341 : 1256 63.
8. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998 339 : 61 8.
9. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27 : 1670 77.
10. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J. Clin. Virol. 2001 21 : 243 53.
11. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 34.
12. Hadziyiannis S, Tassopolous N, Heathcote J et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 51.
13. Fung S, Chae HB, Fontana R et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 90.
14. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 39.
15. Chang TT, Gish RG, Hadziyiannis SJ, Cianciara J, Rizzetto M, Schiff ER. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 129 : 1198 1209.
16. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 2001 107 : 449 55.
17. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 1998 42 : 3200 8.
18. Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 2001 184 : 1236 45.
19. de Man RA, Wolters LM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001 34 : 578 82.
20. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002 123 : 1831 38.
21. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1001 10.
22. Lai CL, Shouval D, Lok A et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1011 20.
23. Matsuyama K, Hayashi K, Miura T et al. The Quantitative assay for HBV-DNA and the detection of HBV-DNA point mutation by Polymerase Chain Reaction -"AMPLICOR HBV MONITOR Test" and "HBV pre Core / Core Promoter Mutation Detection kit Kan Tan Sui 2000 41 : 59 71.
24. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 35.
25. Ichida F, Tsuji T, Omata M et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int. Hepatology. Commun. 1996 6 : 112 19.
26. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 24 : 711 13.
27. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 24 : 714 17.
28. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 2004 48 : 3498 7.
29. Colonno R, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naïve patients. Hepatology 2006 44 : 1656 65.